1. Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma

   • Shu Shimada
   • Shinji Tanaka

   Invited Review Article 28 May 2022 Pages: 1101 - 1109

   

2. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma

   • Masatoshi Kudo

   Invited Review Article Open access 08 May 2022 Pages: 1110 - 1119

   

3. The roles and limitations of bevacizumab in the treatment of ovarian cancer

   • Hidekatsu Nakai
   • Noriomi Matsumura

   Review Article 27 April 2022 Pages: 1120 - 1126

   

4. Prognostic value of myosteatosis in patients with lung cancer: a systematic review and meta-analysis

   • Shaofang Feng
   • Huiwen Mu
   • Yubing Zhu

   Review Article 23 May 2022 Pages: 1127 - 1138

   

5. Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801

   • Shinobu Hosokawa
   • Eiki Ichihara
   • Katsuyuki Kiura

   Original Article 10 May 2022 Pages: 1139 - 1144

   

6. Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer

   • Hongjuan Zheng
   • Chenyang Ge
   • Jinlin Du

   Original Article 10 April 2022 Pages: 1145 - 1153

   

7. Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study

   • Daisuke Sakai
   • Takeshi Omori
   • Yuichiro Doki

   Original Article Open access 30 April 2022 Pages: 1154 - 1163

   

8. Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors

   • Ryugo Teranishi
   • Tsuyoshi Takahashi
   • Yuichiro Doki

   Original Article 18 April 2022 Pages: 1164 - 1172

   

9. Establishment and validation of a nomogram for predicting potential lateral pelvic lymph node metastasis in low rectal cancer

   • Atsuhiko Sumii
   • Koya Hida
   • Masahiko Watanabe

   Original Article 12 April 2022 Pages: 1173 - 1179

   

10. Performance of Idylla^™ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer

    • Yusuke Makutani
    • Kazuko Sakai
    • Junichiro Kawamura

    Original Article Open access 26 April 2022 Pages: 1180 - 1187

    

11. The impact of S-1 for the patient with lymph nodal metastasis biliary tract cancer as adjuvant chemotherapy: a multicenter database analysis

    • Ryoga Hamura
    • Koichiro Haruki
    • Toru Ikegami

    Original Article 15 April 2022 Pages: 1188 - 1195

    

12. Efficacy of EUS-guided celiac plexus neurolysis in combination with EUS-guided celiac ganglia neurolysis for pancreatic cancer-associated pain: a multicenter prospective trial

    • Ken Kamata
    • Makiko Kinoshita
    • Masayuki Kitano

    Original Article 12 April 2022 Pages: 1196 - 1201

    

13. What has changed in malignant mesothelioma between 1990 and 2019? A time- series analyses in Turkey

    • Selma Metintas
    • Guntulu Ak
    • Muzaffer Metintas

    Original Article 21 April 2022 Pages: 1202 - 1211

    

14. Spread of lymph node metastasis and adjuvant therapy for distal cholangiocarcinoma

    • Hiroshi Kurahara
    • Yuko Mataki
    • Takao Ohtsuka

    Original Article 11 May 2022 Pages: 1212 - 1221

    

15. Overexpression of miR-17 predicts adverse prognosis and disease recurrence for acute myeloid leukemia

    • Yang Cao
    • Yue Liu
    • Xiaoying Zhang

    Original Article Open access 10 May 2022 Pages: 1222 - 1232